NL-OMON28980招募中不适用
Alemtuzumab or rituximab induction in ABO-incompatible kidney transplantation.
investigator-drivenErasmus Medical Center Rotterdam0 个研究点目标入组 100 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •Recipients of an ABO-incompatible kidney transplant aged 18 years or older.
排除标准
- •Recipients of an ABO-compatible kidney allograft.
研究者
相似试验
进行中（未招募）
不适用
Therapy with Alemtuzumab (Mabcampath) in patients with acute Lymphoblastic leukemia either refractoy or in relapse. Phase II, multicentric, not randomized study.EUCTR2004-001739-53-ITG.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO
尚未招募
2 期
Investigating the efficacy of an Adjuvant immunotherapy for preventing colorectal liver metastases - The CCaLM trialColon cancerOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonCancer - Bowel - Back passage (rectum) or large bowel (colon)ACTRN12623001333606St George Hospital66
撤回
不适用
Alemtuzumab and Rituximab in Aplastic AnemiaAplastic AnemiaNCT01408342Hospital Universitario Dr. Jose E. Gonzalez
进行中（未招募）
1 期
Will a single dose of Rituximab treatment, when taken with anti thyroid drugs for 1 year, stop the over-activity of the thyroid gland from returning once you stop ATD treatment?EUCTR2016-000209-35-GBewcastle upon Tyne Hospitals NHS Foundation Trust27
尚未招募
不适用
Rituximab administration for chronic antibody-mediated rejection after kidney transplantatioAntibody-mediated rejection after kidney transplantationJPRN-UMIN000018567Department of Nephrology and Hypertension, Saitama Medical Center, Saitama Medical University1